Latest & greatest articles for folic acid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for folic acid

81. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.

Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. 12190367 2002 08 22 2002 09 03 2016 10 17 0098-7484 288 8 2002 Aug 28 JAMA JAMA Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. 973-9 Plasma (...) to April 1999 and enrolled after successful angioplasty of at least 1 significant coronary stenosis (> or = 50%). Participants were randomly assigned to receive a combination of folic acid (1 mg/d), vitamin B12 (cyanocobalamin, 400 micro g/d), and vitamin B6 (pyridoxine hydrochloride, 10 mg/d) (n = 272) or placebo (n = 281) for 6 months. Composite end point of major adverse events defined as death, nonfatal myocardial infarction, and need for repeat revascularization, evaluated at 6 months and 1 year

JAMA2002

82. Quantifying the effect of folic acid.

Quantifying the effect of folic acid. BACKGROUND: Folic acid is known to prevent neural-tube defects (NTDs) but the size of the effect for a given dose is unclear. We aimed to quantify such an effect. METHODS: We used published data from 13 studies of folic acid supplementation on serum folate concentrations and results from a large cohort study of the risk of NTDs according to serum folate, to measure the preventive effect of specified increases in intake of folic acid. FINDINGS: Serum folate (...) concentrations increase by 0.94 ng/mL (95% CI 0.77-1.10) for every 0.1 mg/day increase in folic acid intake in women aged 20-35 years, and about double that in people aged 40-65. Every doubling of serum folate concentration roughly halves the risk of an NTD. These two effects can be combined to predict the reduction in risk according to intake of extra folic acid and background serum folate concentration. Such results predict that the preventive effect is greater in women with low serum folate than in those

Lancet2001

83. Folic acid supplements during pregnancy and risk of miscarriage.

Folic acid supplements during pregnancy and risk of miscarriage. BACKGROUND: Although taking supplements that contain 400 microg of folic acid before and during early pregnancy reduces a woman's risk for having a baby with a neural-tube defect (NTD), the effects of such supplements on other pregnancy outcomes remain unclear. We examined whether the use of such supplements affects the occurrence of miscarriage. METHODS: Participants were women in China who had taken part in a recent folic acid (...) campaign to prevent NTDs and who had registered in this campaign before they became pregnant for the first time. We examined the risk for miscarriage among women who had confirmed pregnancies and who had or had not taken pills containing only 400 microg of folic acid before and during early pregnancy. RESULTS: The overall rate of miscarriage was 9.1% (2155/23806). The rates of miscarriage among women who had and had not taken folic acid pills before and during the first trimester were 9.0% and 9.3

Lancet2001

84. Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour.

Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Power Shortage: clinical trials t... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2001 ) Volume: 135 , Issue: 2 , Pages: 133-137 PubMed: Available from or Find this paper at: Abstract Large randomized, controlled trials of total homocysteine-lowering (...) therapy for the potential reduction of cardiovascular disease outcomes are ongoing in the United States and Canada. These trials are the Vitamin Intervention for Stroke Prevention (VISP) trial, the Women's Antioxidant Cardiovascular Disease Study (WACS), and the Heart Outcomes Prevention Evaluation (HOPE-2). However, the dramatic effect of policies mandating fortification of cereal grain flour products with folic acid may reduce the statistical power of these trials. All three trials assume

Annals of Internal Medicine2001

85. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.

Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. 10683000 2000 03 02 2000 03 02 2015 11 19 0140-6736 355 9203 2000 Feb 12 Lancet (London, England) Lancet Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. 517-22 A high plasma homocysteine concentration is associated (...) with increased risk of atherothrombotic disease. We investigated the effects of homocysteine-lowering treatment (folic acid plus vitamin B6) on markers of subclinical atherosclerosis among healthy siblings of patients with premature atherothrombotic disease. We did a randomised, placebo-controlled trial among 158 healthy siblings of 167 patients with premature atherothrombotic disease. 80 were assigned placebo and 78 were assigned 5 mg folic acid and 250 mg vitamin B6 daily for 2 years. The primary endpoint

Lancet2000

86. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. OBJECTIVES: To assess the effects of folic acid and folinic acid in reducing the mucosal and gastrointestinal (GI) and haematologic side effects of low-dose of Methotrexate (MTX) in patients with Rheumatoid Arthritis (RA) and to determine whether or not folate supplementation alters MTX efficacy. SEARCH STRATEGY: We searched the Cochrane Controlled Clinical Trial's Register (CCTR (...) languages were included. Principal investigators were also contacted in order to look for unpublished literature. SELECTION CRITERIA: We selected all double-blind, randomized, placebo-controlled, clinical trials (RCTs), in which adult RA patients were treated with a low dose of MTX (<20 mg / week) concurrently with folate supplementation. DATA COLLECTION AND ANALYSIS: Two observers extracted the data and assessed the quality of the trials. (BS, Z0) The overall treatment effect across trials

Cochrane2000

87. Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials

Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials Homocysteine Lowering Trialists' Collaboration Authors' objectives To determine the size of reduction in homocysteine concentrations produced by dietary supplementation with folic acid and with vitamins (...) B12 or B6. Searching English and non-English language studies were sought in MEDLINE. The reference lists were scanned and personal contact was made with relevant investigators. Study selection Study designs of evaluations included in the review Published and unpublished randomised controlled trials (RCTs) were included if they had assessed the effects on blood homocysteine concentrations of folic acid supplements with or without the addition of vitamins B6 or B12. Excluded were studies which did

DARE.1998

88. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.

Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. 9535664 1998 04 09 1998 04 09 2015 11 19 0028-4793 338 15 1998 Apr 09 The New England journal of medicine N. Engl. J. Med. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. 1009-15 The Food and Drug Administration (FDA) has recommended that cereal-grain products be fortified with folic acid (...) to prevent congenital neural-tube defects. Since folic acid supplementation reduces levels of plasma homocyst(e)ine, or plasma total homocysteine, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid fortification might reduce plasma homocyst(e)ine levels. To test this hypothesis, we assessed the effects of breakfast cereals fortified with three levels of folic acid, and also containing the recommended dietary allowances of vitamins B6 and B12, in a randomized

NEJM1998

89. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects.

Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. 9400511 1998 01 08 1998 01 08 2015 06 16 0140-6736 350 9092 1997 Dec 06 Lancet (London, England) Lancet Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. 1666-9 Although a daily supplement of 400 micrograms folic acid has been shown to prevent neural-tube defects (NTD), most women do not take the recommended supplement. Thus, food fortification (...) is to be introduced in the USA and is being considered in the UK. Because of safety concerns, the USA has chosen a level of fortification that will increase the average woman's intake by only 100 micrograms. Such an increase, although safe, may be ineffective; but a trial to assess its efficacy would be unethical. Because women with red-cell folate concentrations above 400 micrograms/L have a very low risk of NTD, we undertook a randomised trial of several folic acid doses to find out how much is needed to reach

Lancet1997

90. Folic acid fortification of grain: an economic analysis

Folic acid fortification of grain: an economic analysis Folic acid fortification of grain: an economic analysis Folic acid fortification of grain: an economic analysis Romano P S, Waitzman N J, Scheffler R M, Pi R D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Fortification of grain with folic acid to prevent neural tube defects (spina bifida and anencephaly). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Women of child-bearing age (11 to 50 years). Setting Community. The economic study was carried out in California, USA. Dates to which data relate Data on the effectiveness of folic acid fortification was taken from two studies published in 1989 and 1991. The data

NHS Economic Evaluation Database.1995